Serum samples were tested for HA anti-dsDNA IgG antibodies (ELISA, INOVA Diagnostics), anti-C1q IgG antibodies (ELISA, INOVA Diagnostics), and enzymatic serum creatinine (MODULAR P, Roche Diagnostics, Indianapolis, IN). The presence and concentration of NGAL in serum and urine were detected using the NGAL Test reagent kit (BioPorto Diagnostics, Hellerup, Denmark), a particle-enhanced turbidimetric immunoassay with application parameters for several automated methods; for this study the Roche cobas c501 was used. All testings were performed at ARUP Laboratories following manufacturers' instructions. Manufacturers' recommended cut-off values were utilized for HA dsDNA (>30 IU/mL) and anti-C1q (540 units) assays. Reference ranges for serum creatinine (35.4-
Elisa
Manufactured by Inova Diagnostics
Sourced in United States
ELISA (Enzyme-Linked Immunosorbent Assay) is a laboratory technique used to detect and quantify specific proteins, antibodies, or other analytes in a sample. It relies on the specific binding of an antigen and an antibody, which is then detected and quantified through an enzymatic reaction.
Automatically generated - may contain errors
Lab products found in correlation
Diastat, by Axis-Shield (3 mentions)
Bioplex 2200, by Bio-Rad (2 mentions)
Horseradish peroxidase conjugated anti mouse antibody, by Agilent Technologies (1 mentions)
Line immunoassays, by EUROIMMUN (1 mentions)
Line immuno assay, by Fujirebio (1 mentions)
Hep 2 cells, by Inova Diagnostics (1 mentions)
Labospect 008, by Hitachi (1 mentions)
Dxc 700 au, by Beckman Coulter (1 mentions)
Synergy ht plate reader, by Agilent Technologies (1 mentions)
Magnetic bead panel, by Merck Group (1 mentions)
Magpix, by DiaSorin (1 mentions)
Elisa kit, by R&D Systems (1 mentions)
Cobas c501, by Roche (1 mentions)
Modular p, by Roche (1 mentions)
34 protocols using elisa
1
Serological Biomarkers in Lupus
2
Autoantibody Detection in Autoimmune Myopathy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Autoantibodies to HMGCR were detected by an addressable laser bead immunoassay (ALBIA) using a laboratory developed test (Mitogen Advanced Diagnostics, Calgary, AB, Canada) that was validated and then replaced by a commercially available ELISA (Inova Diagnostics, San Diego, CA, USA). Other AIM autoantibodies were detected by a commercial line immunoassay (Euroimmun GmbH, Lübeck, Germany) and included those directed to Jo-1, Mi2-α, Mi2-β, MDA5, NXP2, TIF1γ, PL7, PL12, PM/Scl75, PM/Scl100, Ku, SRP, EJ, OJ, and Ro52/TRIM21 autoantigens.
3
PBC Patients' Health-Related Quality of Life
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients with PBC fulfilled the diagnostic criteria established by the European Association for the Study of Liver (EASL) [17 (link)]. The study was performed in a homogenous group of Caucasian patients with PBC who were treated in two Polish liver transplant centres, in Szczecin and in Warsaw. Patients recruited at both sites did not differ in terms of demographic, clinical, and biochemical characteristics (data not shown). One hundred and seven (36.5%) subjects were diagnosed with liver cirrhosis, by either liver biopsy or imaging screening. Data on cirrhosis status were not available in 28 patients. Clinical and laboratory features of analyzed subjects are summarized in Table 1 . Health-related quality of life (HRQoL) was assessed with disease-specific questionnaires (PBC-40 and PBC-27) [18 (link)]. PBC-specific AMA were tested by ELISA (Inova Diagnostics, San Diego, CA, USA).
Control group was comprised of 258 age- and gender-matched subjects without liver diseases. These controls were also tested for AMA using the same ELISA.
Control group was comprised of 258 age- and gender-matched subjects without liver diseases. These controls were also tested for AMA using the same ELISA.
4
Longitudinal Evaluation of Rheumatoid Arthritis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patient demographic data and clinical characteristics, disease activity, and laboratory parameters were assessed at baseline and annually thereafter. Digitized hand radiographs were collected at baseline and at 2, 5, 7, 10, and 12 years and will be collected to at least 15 years (Fig. 1 ). Hand BMD was measured at the metacarpal bones of the second, third, and fourth digits using DXR–BMD (DXR-online, Sectra Imtec AB, Linköping, Sweden) as described previously [28 (link)]. Anti-CCP2 antibody level was measured using a validated ELISA (Inova Diagnostics, San Diego, California, USA until its discontinuation in 2011; thereafter Euro-Diagnostica [distributed by IBL-America, Minneapolis, Minnesota, USA]). Patient-reported outcomes were assessed with a follow-up questionnaire every 6 months (Fig. 1 ).![]()
Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) design
5
Laboratory Biomarkers in Autoimmune Diseases
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Laboratory analyses were carried out at the Clinical Chemistry unit, Linköping University Hospital or the Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, and included complement components (C3, C4, and C3d by nephelometry; classic hemolytic complement function), erythrocyte sedimentation rate (ESR), hemoglobin concentration, and blood cell counts (leukocytes, lymphocytes, neutrophils, basophils, monocytes, platelets). Urinalysis by urinary dipstick was assessed with regard to urinary erythrocytes (cells/µL) and urinary albumin (g/L). Renal function was measured by estimated glomerular filtration rate (eGFR) based on plasma creatinine [45 (link)]. Levels of myeloperoxidase (MPO)- and proteinase 3 (PR3)-ANCA were measured using sensitive fluorescence enzyme immunoassay (FEIA) [46 (link)]. Anti-C1q antibodies were analyzed using ELISA (Inova Diagnostics, San Diego, USA) [47 (link)].
The levels of C3, C4, and ESR were divided based on reference values from the accredited Clinical Chemistry unit, Linköping. C3 and C4 below 0.7 and 0.13 g/L, respectively, and ESR above 30 mm/h were considered subnormal/abnormal.
The levels of C3, C4, and ESR were divided based on reference values from the accredited Clinical Chemistry unit, Linköping. C3 and C4 below 0.7 and 0.13 g/L, respectively, and ESR above 30 mm/h were considered subnormal/abnormal.
6
Inflammatory Biomarkers and Antibodies
7
Autoimmune Antiphospholipid Antibody Analysis
8
Autoantibody Reactivity Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Reactivity at 1:101 serum dilution to purified gp210 and sp100, and to recombinant CENP-A/B was determined by ELISA (INOVA Diagnostics, USA), according to the manufacturer’s instructions. These ELISA assays were performed only on samples that showed nuclear envelope, multiple nuclear dots, or centromere staining patterns in the HEp-2 IFA test in at least one of the serial samples.
9
Autoantibody Screening in Systemic Sclerosis
10
Serological Biomarkers in Inflammatory Bowel Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum aGP2 IgG and IgA were determined by ELISA (Generic Assays, Dahlewitz/Berlin, Germany), according to the manufacturer’s instructions.21 (link) The cutoff value for positivity was set to 15 U/ml for IgG aGP2 and 10 U/ml for IgA aGP2, as recommended by the manufacturer. Serum IgG ASCA and IgA ASCA were determined by ELISA (Inova Diagnostics, San Diego, USA). Values above 25 U/ml were considered as positive according to the manufacturer’s instructions. Serum IgG pANCA and IgA pANCA were tested by indirect immunofluorescent assay (IFA) (Euroimmune, Luebeck, Germany), in accordance with the manufacturer’s instructions. IFA testings were performed starting with an initial dilution of 1/10. Serial dilutions of 1/20, 1/40, 1/80, and 1/160 were further performed for all positive samples. Two experienced technologists interpreted the results.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!